News /
2
min read /
August 27, 2022

Big Health Shortlisted as Finalists in this year’s Healthcare Excellence Through Technology Awards

by

We are delighted to announce that we have been shortlisted as finalists in this year’s Healthcare Excellence Through Technology (HETT) Awards under the category, ‘Best Primary Care Digital Project’. The HETT awards are designed to showcase champions of digital health innovation and highlight great stories of transformation, with the Best Primary Care Digital Project award recognising projects adopting a digital-first model in the provision of primary care.

Big Health’s digital therapeutics, Sleepio for insomnia and Daylight for worry and anxiety, have been recognised as innovators in supporting equitable access and reducing health inequalities through the provision of computerised cognitive behaviour therapy (cCBT) throughout Scotland.

With a steep increase in demand for CBT services for mental health, Big Health has been able to support this growing demand, with results from the 2012 clinical trial for Sleepio evidencing that 76% of patients experienced improvement in their sleep.* Additionally the 2020 UK clinical trial for Daylight evidenced that 71% of patients experienced reductions in anxiety. **

The awards will take place in London this November. Best of luck to all finalists!

*Sleepio study source: Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomised, placebo-controlled trial of online cognitive behavioural therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781;

**Daylight study source: Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A., … & Espie, C. A. (2020). Efficacy of digital cognitive behavioural therapy for moderate‐to‐severe symptoms of generalised anxiety disorder: A randomised controlled trial. Depression and anxiety, 37(12), 1168-1178.

During the COVID-19 public health emergency, Sleepio and Daylight are being made available as treatments for insomnia disorder and generalized anxiety disorder (GAD), respectively, without a prescription. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia disorder and GAD, respectively.

1. Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., & Denberg, T. D. (2016). Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125-133.2. Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., … & Spiegelhalder, K. (2017). European guideline for the diagnosis and treatment of insomnia. Journal of Sleep Research, 26(6), 675-700.3. Wilson, S., Anderson, K., Baldwin, D., Dijk, D. J., Espie, A., Espie, C., … & Sharpley, A. (2019). British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. Journal of Psychopharmacology, 33(8), 923-947.4. King’s Technology Evaluation Centre. (2017, November 9). Overview: Health app: SLEEPIO for adults with poor Sleep: Advice. NICE. https://www.nice.org.uk/advice/mib129.5. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.6. Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A., … & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate‐to‐severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and Anxiety, 37(12), 1168-1178.

DOC-3046 Effective 11/2023